Fatih Noyan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fatih Noyan has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Matthias Hardtke-Wolenski
Dept. of Gastroenterology Hepatology, Infectious Disease and Endocrinology Hannover Medical School Hannover Germany
11 shared publications - Laura Elisa Buitrago-Molina
Department of Gastroenterology, Hepatology, Infectious Diseases & Endocrinology, Hannover Medical School, 30625 Hannover, Germany
7 shared publications - Heiner Wedemeyer
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
6 shared publications - Elmar Jaeckel
Department of Gastroenterology, Hepatology, Infectious Diseases & Endocrinology, Hannover Medical School, 30625 Hannover, Germany
4 shared publications - Tobias Riet
Department of Gastroenterology, Hepatology, Infectious Diseases & Endocrinology, Hannover Medical School, 30625 Hannover, Germany
4 shared publications - Andrea Schienke
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, 30625 Hannover, Germany
3 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8219
The Transmembrane Envelope Protein of Porcine Endogenous Retroviruses Modulates Cytokine Release and Gene Expression in Human Immune Cells
Porcine endogenous retroviruses (PERVs), their transmembrane envelope protein p15E and peptides corresponding to a domain in p15E that is highly conserved among retroviruses, the immunosuppressive (isu) domain, demonstrated immunosuppressive properties. They inhibited in vitro immune reactions, and induced release of IL-6 and IL-10 in human peripheral blood mononuclear cells (PBMCs). We recently showed that p15E of PERV expressed on 293T cells reduced MHC expression, induced cytokine release in co-incubated human PBMCs, and inhibited cytotoxic cells. The cell-surface expression of p15E was chosen to simulate an artificially introduced expression on a transplant. Here, a new construct with a higher expression of p15E and consequently higher effects on cytokine release was designed and used. An intracellular cytokine assay was newly developed and applied, whereas a commercial cytokine array was used to analyze the release of 105 cytokines into the supernatant. The differential gene expression was analyzed by sequencing the RNA of PBMCs incubated with p15E-expressing and wild-type 293T cells. PERV p15E induced an elevated expression of IL-10, IL-6 and 24 other cytokines and modulated the expression of hundreds of genes. Furthermore, coating porcine L23 cells with the synthetic isu peptide of the PERV p15E protein and subsequently co-incubating them with human PBMCs induced IL-10 production, whereas direct addition of the peptide to PBMCs alone did not induce cytokine production. These results demonstrate that the PERV p15E protein can modulate cytokine release by human immune cells and suppress their cytotoxic activity. This immunomodulatory property may have potential applications in protecting transplanted tissues from immune-mediated rejection.
- 15 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8219
Open AccessThe Transmembrane Envelope Protein of Porcine Endogenous Retroviruses Modulates Cytokine Release and Gene Expression in Human Immune Cells
Porcine endogenous retroviruses (PERVs), their transmembrane envelope protein p15E and peptides corresponding to a domain in p15E that is highly conserved among retroviruses, the immunosuppressive (isu) domain, demonstrated immunosuppressive properties. They inhibited in vitro immune reactions, and induced release of IL-6 and IL-10 in human peripheral blood mononuclear cells (PBMCs). We recently showed that p15E of PERV expressed on 293T cells reduced MHC expression, induced cytokine release in co-incubated human PBMCs, and inhibited cytotoxic cells. The cell-surface expression of p15E was chosen to simulate an artificially introduced expression on a transplant. Here, a new construct with a higher expression of p15E and consequently higher effects on cytokine release was designed and used. An intracellular cytokine assay was newly developed and applied, whereas a commercial cytokine array was used to analyze the release of 105 cytokines into the supernatant. The differential gene expression was analyzed by sequencing the RNA of PBMCs incubated with p15E-expressing and wild-type 293T cells. PERV p15E induced an elevated expression of IL-10, IL-6 and 24 other cytokines and modulated the expression of hundreds of genes. Furthermore, coating porcine L23 cells with the synthetic isu peptide of the PERV p15E protein and subsequently co-incubating them with human PBMCs induced IL-10 production, whereas direct addition of the peptide to PBMCs alone did not induce cytokine production. These results demonstrate that the PERV p15E protein can modulate cytokine release by human immune cells and suppress their cytotoxic activity. This immunomodulatory property may have potential applications in protecting transplanted tissues from immune-mediated rejection.
- Open Access
- 25 August 2026
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 13
Late TNFα blockade is associated with systemic immune rewiring without disease control in established experimental autoimmune hepatitis
- 25 August 2026
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 13
Open AccessLate TNFα blockade is associated with systemic immune rewiring without disease control in established experimental autoimmune hepatitis
- Open Access
- 14 August 2026
- Published by MDPI AG in Preprints.org
The Transmembrane Envelope Protein of Porcine Endogenous Retroviruses Modulates Cytokine Release and Gene Expression in Human Immune Cells
Porcine endogenous retroviruses (PERVs), their transmembrane envelope protein p15E and peptides corresponding to a highly conserved among all retroviruses domain in p15E, the immunosuppressive (isu) domain, demonstrated immunosuppressive properties. They inhibited in vitro immune reactions, and induced release of IL-6 and IL-10 in human peripheral blood mononuclear cells (PBMCs). We recently showed that p15E of PERV expressed on 293T cells reduced the MHC expression and induced cytokine release in co-incubated human PBMCs. Furthermore, expression of p15E inhibited cytotoxic cells. Here, a new construct with a higher expression of p15E and consequently higher effects on cytokine release was designed and used. Furthermore, a newly developed cytokine assay measuring intracellular cytokine production and a cytokine array to analyze the release of 105 cytokines into the supernatant was developed. The differential gene expression was analyzed by sequencing the RNA of PBMCs incubated with p15E-expressing and wild-type 293T cells. PERV p15E induced an elevated expression of IL-10, IL-6 and 24 other cytokines and modulated the expression of hundreds of genes. Furthermore, coating porcine L23 cells with the synthetic isu peptide of the PERV p15E protein and subsequently co-incubating them with human PBMCs induced IL-10 production, whereas direct addition of the peptide to PBMCs alone did not induce cytokine production. These results indicate that the PERV p15E protein is capable of modulating cytokine release by human PBMCs and inhibiting their cytotoxic activity.
- 14 August 2026
- Published by MDPI AG in Preprints.org
Open AccessThe Transmembrane Envelope Protein of Porcine Endogenous Retroviruses Modulates Cytokine Release and Gene Expression in Human Immune Cells
Porcine endogenous retroviruses (PERVs), their transmembrane envelope protein p15E and peptides corresponding to a highly conserved among all retroviruses domain in p15E, the immunosuppressive (isu) domain, demonstrated immunosuppressive properties. They inhibited in vitro immune reactions, and induced release of IL-6 and IL-10 in human peripheral blood mononuclear cells (PBMCs). We recently showed that p15E of PERV expressed on 293T cells reduced the MHC expression and induced cytokine release in co-incubated human PBMCs. Furthermore, expression of p15E inhibited cytotoxic cells. Here, a new construct with a higher expression of p15E and consequently higher effects on cytokine release was designed and used. Furthermore, a newly developed cytokine assay measuring intracellular cytokine production and a cytokine array to analyze the release of 105 cytokines into the supernatant was developed. The differential gene expression was analyzed by sequencing the RNA of PBMCs incubated with p15E-expressing and wild-type 293T cells. PERV p15E induced an elevated expression of IL-10, IL-6 and 24 other cytokines and modulated the expression of hundreds of genes. Furthermore, coating porcine L23 cells with the synthetic isu peptide of the PERV p15E protein and subsequently co-incubating them with human PBMCs induced IL-10 production, whereas direct addition of the peptide to PBMCs alone did not induce cytokine production. These results indicate that the PERV p15E protein is capable of modulating cytokine release by human PBMCs and inhibiting their cytotoxic activity.
- Open Access
Engineering CAR‐Tregs with Phage‐Selected scFv Enables a New Paradigm for Immune Regulation
Regulatory T cells (Tregs) are central to immune tolerance, yet antigen‐specific cell therapies lag behind cytotoxic CAR‐T approaches. Most CAR‐Treg programs still use single‐chain variable fragments (scFvs) derived from monoclonal antibodies optimized for effector function, a bias that may promote CAR clustering, tonic signaling, and lineage instability. Here, we propose a phage‐first binder discovery framework for CAR‐Tregs and state testable hypotheses linking phage‐display selection pressures to scFv biophysical properties and Treg fate. We hypothesize that multi‐parameter selection and counter‐selection can enrich scFvs with moderate affinity, low polyspecificity, and improved framework stability, thereby lowering tonic signaling in defined backbone architectures and preserving FOXP3/TSDR stability under inflammatory stress. We outline a falsifiable two‐phase roadmap—bench triage followed by mechanistic and preclinical validation to determine how scFv properties, expression level, and intracellular signaling domains define an optimal tonic window for durable immune regulation.
Open AccessEngineering CAR‐Tregs with Phage‐Selected scFv Enables a New Paradigm for Immune Regulation
Regulatory T cells (Tregs) are central to immune tolerance, yet antigen‐specific cell therapies lag behind cytotoxic CAR‐T approaches. Most CAR‐Treg programs still use single‐chain variable fragments (scFvs) derived from monoclonal antibodies optimized for effector function, a bias that may promote CAR clustering, tonic signaling, and lineage instability. Here, we propose a phage‐first binder discovery framework for CAR‐Tregs and state testable hypotheses linking phage‐display selection pressures to scFv biophysical properties and Treg fate. We hypothesize that multi‐parameter selection and counter‐selection can enrich scFvs with moderate affinity, low polyspecificity, and improved framework stability, thereby lowering tonic signaling in defined backbone architectures and preserving FOXP3/TSDR stability under inflammatory stress. We outline a falsifiable two‐phase roadmap—bench triage followed by mechanistic and preclinical validation to determine how scFv properties, expression level, and intracellular signaling domains define an optimal tonic window for durable immune regulation.
- 10 April 2026
- Published by Elsevier in Molecular Therapy
- Vol. 34 (5) , 2529-2530
Programming precision tolerance: Antigen-gated IL-10 release sharpens CAR-Treg therapy
- 10 April 2026
- Published by Elsevier in Molecular Therapy
- Vol. 34 (5) , 2529-2530
Programming precision tolerance: Antigen-gated IL-10 release sharpens CAR-Treg therapy
- Open Access
Graft-Specific Regulatory T Cells for Long-Lasting, Local Tolerance Induction
Background: Solid organ transplantation is hindered by immune-mediated chronic graft dysfunction and the side effects of immunosuppressive therapy. Regulatory T cells (Tregs) are crucial for modulating immune responses post-transplantation; however, the transfer of polyspecific Tregs alone is insufficient to induce allotolerance in rodent models. Methods: To enhance the efficacy of adoptive Treg therapy, we investigated different immune interventions in the recipients. By utilizing an immunogenic skin transplant model and existing transplantation medicine reagents, we facilitated the clinical translation of our findings. Specifically, antigen-specific Tregs were used. Results: Our study demonstrated that combining the available induction therapies with drug-induced T-cell proliferation due to lymphopenia effectively increased the Treg/T effector ratios. This results in significant Treg accumulation within the graft, leading to long-term tolerance after the transfer of antigen-specific Tregs. Importantly, all the animals achieved operational tolerance, which boosted the presence of adoptively transferred Tregs within the graft. Conclusions: This protocol offers a means to establish tolerance by utilizing antigen-specific Tregs. These results have promising implications for future trials involving adoptive Treg therapy in organ transplantation.
Open AccessGraft-Specific Regulatory T Cells for Long-Lasting, Local Tolerance Induction
Background: Solid organ transplantation is hindered by immune-mediated chronic graft dysfunction and the side effects of immunosuppressive therapy. Regulatory T cells (Tregs) are crucial for modulating immune responses post-transplantation; however, the transfer of polyspecific Tregs alone is insufficient to induce allotolerance in rodent models. Methods: To enhance the efficacy of adoptive Treg therapy, we investigated different immune interventions in the recipients. By utilizing an immunogenic skin transplant model and existing transplantation medicine reagents, we facilitated the clinical translation of our findings. Specifically, antigen-specific Tregs were used. Results: Our study demonstrated that combining the available induction therapies with drug-induced T-cell proliferation due to lymphopenia effectively increased the Treg/T effector ratios. This results in significant Treg accumulation within the graft, leading to long-term tolerance after the transfer of antigen-specific Tregs. Importantly, all the animals achieved operational tolerance, which boosted the presence of adoptively transferred Tregs within the graft. Conclusions: This protocol offers a means to establish tolerance by utilizing antigen-specific Tregs. These results have promising implications for future trials involving adoptive Treg therapy in organ transplantation.
- Open Access
Gene editing of CD3 epsilon gene to redirect regulatory T cells for adoptive T cell transfer
I. Adoptive transfer of regulatory T cells (Tregs) is a promising strategy to combat immunopathologies in transplantation and autoimmune diseases. Antigen-specific Tregs are more effective in modulating undesired immune reactions, but their low frequency in peripheral blood poses challenges for manufacturing and their clinical application. Chimeric antigen receptors (CARs) have been used to redirect the specificity of Tregs, employing retroviral vectors. However, retroviral gene transfer is costly, time consuming, and raises safety issues. Here, we explored non-viral gene editing to redirect Tregs with CARs, using HLA-A2-specific constructs for proof-of-concept studies in transplantation models. We introduce a virus-free CRISPR-Cas12a approach to integrate an antigen-binding domain into the CD3 epsilon ( CD3ε ) gene, generating Tregs expressing a T cell receptor fusion construct (TruC). These CD3ε -TruC Tregs exhibit potent antigen-dependent activation while maintaining responsiveness to TCR/CD3 stimulation. This enables preferential enrichment of TruC-redirected Tregs via repetitive CD3/CD28-stimulation in a GMP-compatible expansion system. Non-viral gene edited CD3ε -TruC Tregs retained their phenotypic, epigenetic, and functional identity. In a humanized mouse model, HLA-A2-specific CD3ε -TruC Tregs demonstrate superior protection of allogeneic HLA-A2 + skin grafts from rejection compared to polyclonal Tregs. This approach provides a pathway for developing clinical-grade CD3ε -TruC-based Treg cell products for transplantation immunotherapy and other immunopathologies.
Open AccessGene editing of CD3 epsilon gene to redirect regulatory T cells for adoptive T cell transfer
I. Adoptive transfer of regulatory T cells (Tregs) is a promising strategy to combat immunopathologies in transplantation and autoimmune diseases. Antigen-specific Tregs are more effective in modulating undesired immune reactions, but their low frequency in peripheral blood poses challenges for manufacturing and their clinical application. Chimeric antigen receptors (CARs) have been used to redirect the specificity of Tregs, employing retroviral vectors. However, retroviral gene transfer is costly, time consuming, and raises safety issues. Here, we explored non-viral gene editing to redirect Tregs with CARs, using HLA-A2-specific constructs for proof-of-concept studies in transplantation models. We introduce a virus-free CRISPR-Cas12a approach to integrate an antigen-binding domain into the CD3 epsilon ( CD3ε ) gene, generating Tregs expressing a T cell receptor fusion construct (TruC). These CD3ε -TruC Tregs exhibit potent antigen-dependent activation while maintaining responsiveness to TCR/CD3 stimulation. This enables preferential enrichment of TruC-redirected Tregs via repetitive CD3/CD28-stimulation in a GMP-compatible expansion system. Non-viral gene edited CD3ε -TruC Tregs retained their phenotypic, epigenetic, and functional identity. In a humanized mouse model, HLA-A2-specific CD3ε -TruC Tregs demonstrate superior protection of allogeneic HLA-A2 + skin grafts from rejection compared to polyclonal Tregs. This approach provides a pathway for developing clinical-grade CD3ε -TruC-based Treg cell products for transplantation immunotherapy and other immunopathologies.
- Open Access
Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease
Background: Alzheimer’s disease (AD) is a neurodegenerative disease that remains uncured. Its pathogenesis is characterized by the formation of β-amyloid (Aβ) plaques. The use of antigen-specific regulatory T cells (Tregs) through adoptive transfer has shown promise for the treatment of many inflammatory diseases, although the effectiveness of polyspecific Tregs is limited. Obtaining a sufficient number of antigen-specific Tregs from patients remains challenging. Aims and Methods: To address this problem, we used an antibody-like single-chain variable fragment from a phage library and subsequently generated a chimeric antigen receptor (CAR) targeting β-amyloid. Results: The β-amyloid-specific CARs obtained were stimulated by both recombinant and membrane-bound Aβ isolated from the murine brain. The generated CAR-Tregs showed a normal Treg phenotype, were antigen-specific activatable, and had suppressive capacity. Conclusion: This study highlights the potential of CAR technology to generate antigen-specific Tregs and presents novel approaches for developing functional CARs.
Open AccessDevelopment of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease
Background: Alzheimer’s disease (AD) is a neurodegenerative disease that remains uncured. Its pathogenesis is characterized by the formation of β-amyloid (Aβ) plaques. The use of antigen-specific regulatory T cells (Tregs) through adoptive transfer has shown promise for the treatment of many inflammatory diseases, although the effectiveness of polyspecific Tregs is limited. Obtaining a sufficient number of antigen-specific Tregs from patients remains challenging. Aims and Methods: To address this problem, we used an antibody-like single-chain variable fragment from a phage library and subsequently generated a chimeric antigen receptor (CAR) targeting β-amyloid. Results: The β-amyloid-specific CARs obtained were stimulated by both recombinant and membrane-bound Aβ isolated from the murine brain. The generated CAR-Tregs showed a normal Treg phenotype, were antigen-specific activatable, and had suppressive capacity. Conclusion: This study highlights the potential of CAR technology to generate antigen-specific Tregs and presents novel approaches for developing functional CARs.
- Open Access
Generation of Chimeric Antigen Receptors against Tetraspanin 7
Adoptive transfer of antigen-specific regulatory T cells (Tregs) has shown promising results in the treatment of autoimmune diseases; however, the use of polyspecific Tregs has limited effects. However, obtaining a sufficient number of antigen-specific Tregs from patients with autoimmune disorders remains challenging. Chimeric antigen receptors (CARs) provide an alternative source of T cells for novel immunotherapies that redirect T cells independently of the MHC. In this study, we aimed to generate antibody-like single-chain variable fragments (scFv) and subsequent CARs against tetraspanin 7 (TSPAN7), a membrane protein highly expressed on the surface of pancreatic beta cells, using phage display technology. We established two methods for generating scFvs against TSPAN7 and other target structures. Moreover, we established novel assays to analyze and quantify their binding abilities. The resulting CARs were functional and activated specifically by the target structure, but could not recognize TSPAN7 on the surface of beta cells. Despite this, this study demonstrates that CAR technology is a powerful tool for generating antigen-specific T cells and provides new approaches for generating functional CARs.
Open AccessGeneration of Chimeric Antigen Receptors against Tetraspanin 7
Adoptive transfer of antigen-specific regulatory T cells (Tregs) has shown promising results in the treatment of autoimmune diseases; however, the use of polyspecific Tregs has limited effects. However, obtaining a sufficient number of antigen-specific Tregs from patients with autoimmune disorders remains challenging. Chimeric antigen receptors (CARs) provide an alternative source of T cells for novel immunotherapies that redirect T cells independently of the MHC. In this study, we aimed to generate antibody-like single-chain variable fragments (scFv) and subsequent CARs against tetraspanin 7 (TSPAN7), a membrane protein highly expressed on the surface of pancreatic beta cells, using phage display technology. We established two methods for generating scFvs against TSPAN7 and other target structures. Moreover, we established novel assays to analyze and quantify their binding abilities. The resulting CARs were functional and activated specifically by the target structure, but could not recognize TSPAN7 on the surface of beta cells. Despite this, this study demonstrates that CAR technology is a powerful tool for generating antigen-specific T cells and provides new approaches for generating functional CARs.
- Open Access
- 22 May 2023
- Published by Elsevier in Journal of Autoimmunity
- Vol. 138, 103057
Supraphysiological FOXP3 expression in human CAR-Tregs results in improved stability, efficacy, and safety of CAR-Treg products for clinical application
- 22 May 2023
- Published by Elsevier in Journal of Autoimmunity
- Vol. 138, 103057
Open AccessSupraphysiological FOXP3 expression in human CAR-Tregs results in improved stability, efficacy, and safety of CAR-Treg products for clinical application